Medacta Group (MOVE) Panoramica del titolo
Medacta Group SA sviluppa, produce e distribuisce dispositivi medici ortopedici e neurochirurgici in America Latina, Nord America, Asia-Pacifico, Medio Oriente e Africa. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 6/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per MOVE dai nostri controlli di rischio.
MOVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Medacta Group SA
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | CHF 134.40 |
| Massimo di 52 settimane | CHF 177.20 |
| Minimo di 52 settimane | CHF 128.00 |
| Beta | 0.99 |
| Variazione di 1 mese | -0.74% |
| Variazione a 3 mesi | -13.74% |
| Variazione di 1 anno | 0.75% |
| Variazione a 3 anni | 10.34% |
| Variazione a 5 anni | 11.07% |
| Variazione dall'IPO | 39.85% |
Notizie e aggiornamenti recenti
Articolo di analisi • Jun 07
What Is Medacta Group SA's (VTX:MOVE) Share Price Doing?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw significant share price movement during...
Aggiornamento della narrazione • Jun 05
MOVE: Earnings Outlook And Dividend Will Support Future Upside Potential
Analysts have nudged their price target on Medacta Group slightly lower to CHF 179.08 from CHF 179.46, reflecting updated fair value assumptions and a modestly lower future P/E multiple, while keeping revenue growth and profit margin expectations essentially unchanged. What's in the News Medacta has been selected to join an international research project focused on recreating dinosaurs from preserved DNA, working alongside Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural Science Museum London (source: company client announcement).Aggiornamento della narrazione • Apr 25
MOVE: Earnings Outlook And Dividend Will Drive Future Upside Potential
Analysts have nudged their price target for Medacta Group slightly lower to CHF 179 from about CHF 181. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that are broadly consistent with previous expectations.Aggiornamento della narrazione • Apr 11
MOVE: Earnings Outlook And Dividend Will Drive Further Upside Potential
Analysts have nudged their price target for Medacta Group slightly higher to CHF181.43 from CHF180.07, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Medacta has joined an international research project focused on recreating dinosaurs from preserved DNA, working with partners including Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural History Museum in London.Recent updates
Articolo di analisi • Jun 07
What Is Medacta Group SA's (VTX:MOVE) Share Price Doing?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw significant share price movement during...Aggiornamento della narrazione • Jun 05
MOVE: Earnings Outlook And Dividend Will Support Future Upside Potential
Analysts have nudged their price target on Medacta Group slightly lower to CHF 179.08 from CHF 179.46, reflecting updated fair value assumptions and a modestly lower future P/E multiple, while keeping revenue growth and profit margin expectations essentially unchanged. What's in the News Medacta has been selected to join an international research project focused on recreating dinosaurs from preserved DNA, working alongside Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural Science Museum London (source: company client announcement).Aggiornamento della narrazione • Apr 25
MOVE: Earnings Outlook And Dividend Will Drive Future Upside Potential
Analysts have nudged their price target for Medacta Group slightly lower to CHF 179 from about CHF 181. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that are broadly consistent with previous expectations.Aggiornamento della narrazione • Apr 11
MOVE: Earnings Outlook And Dividend Will Drive Further Upside Potential
Analysts have nudged their price target for Medacta Group slightly higher to CHF181.43 from CHF180.07, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Medacta has joined an international research project focused on recreating dinosaurs from preserved DNA, working with partners including Resurgence Biotechnology, ETH Zurich, World Regenesis Lab and the Natural History Museum in London.Aggiornamento della narrazione • Mar 28
MOVE: Earnings Outlook And Dividend Will Support Further Upside Potential
Analysts have raised their price target on Medacta Group to CHF 180.07 from CHF 177.36, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News Company issued earnings guidance for 2026, targeting revenue growth in a range of 10% to 14% in constant currency (Key Developments).Aggiornamento della narrazione • Mar 12
MOVE: Slightly Higher Return Hurdle Will Still Support Future Upside
The analyst price target for Medacta Group has been adjusted slightly lower to reflect a revised fair value of about CHF 177.36, with analysts pointing to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: CHF 177.36, slightly lower than the prior estimate of CHF 178.87.Aggiornamento della narrazione • Feb 26
MOVE: Slightly Higher Return Hurdle And Lower P/E Will Still Support Upside
Analysts have maintained their CHF 178.87 price target for Medacta Group, with the slight adjustment in discount rate and lower assumed future P/E multiple reflecting a more cautious stance on valuation assumptions while keeping the overall target level unchanged. Valuation Changes Fair Value: CHF 178.87 remains unchanged, indicating no adjustment to the overall fair value estimate.Aggiornamento della narrazione • Feb 10
MOVE: Higher Growth Assumptions And Richer P/E Will Support Gradual Upside
Analysts have nudged their price target for Medacta Group slightly higher, to €178.87 from €178.20, reflecting updated views on discount rates, revenue growth, profit margins, and the future P/E multiple. Valuation Changes Fair Value: updated slightly higher from €178.20 to €178.87.Aggiornamento della narrazione • Jan 25
MOVE: Modest Assumption Tweaks And Firm Margins Will Underpin Gradual Performance
Analysts have raised their price target on Medacta Group to approximately CHF 178 from about CHF 167, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and a future P/E of roughly 35x in their updated models. Valuation Changes Fair Value: Updated model fair value moves from about CHF 166.69 to roughly CHF 178.20 per share.Articolo di analisi • Jan 21
Subdued Growth No Barrier To Medacta Group SA's (VTX:MOVE) Price
With a price-to-earnings (or "P/E") ratio of 38.5x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...Aggiornamento della narrazione • Jan 08
MOVE: Steady Margins And Refined Assumptions Will Support Gradual Performance
Analysts have nudged their price target on Medacta Group slightly higher to reflect a modestly lower discount rate and a small refinement in assumed future P/E. This suggests a fine tuning of their valuation rather than a major shift in view.Articolo di analisi • Dec 30
Is It Time To Consider Buying Medacta Group SA (VTX:MOVE)?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a double-digit share price...Aggiornamento della narrazione • Dec 25
MOVE: Steady Margins And Fair Pricing Will Support Gradual Performance
Narrative Update on Medacta Group Analysts have modestly raised their price target on Medacta Group, citing a slightly higher long term discount rate and marginally richer future earnings multiple expectations that together point to a fair value of approximately CHF 166.70 per share. Valuation Changes Fair Value Estimate, unchanged at approximately CHF 166.70 per share, indicating no revision to the central valuation outcome.Aggiornamento della narrazione • Dec 11
MOVE: Lower Risk And Steady Margins Will Support Gradual Performance Outlook
Analysts have modestly raised their price target on Medacta Group to approximately CHF 166.70 from around CHF 164.40, reflecting slightly lower perceived risk, a marginally stronger long term profit margin outlook, and a small upward revision to anticipated future valuation multiples. Valuation Changes Fair Value has risen slightly from approximately CHF 164.40 to about CHF 166.70, implying a modest increase in the assessed intrinsic value.Aggiornamento della narrazione • Nov 26
MOVE: Stable Earnings Guidance And Margins Will Support Measured Performance Outlook
Analysts have maintained their price target for Medacta Group at CHF 164.40. They cite steady profit margin expectations and a stable outlook for revenue growth, despite minor adjustments to the discount rate.Aggiornamento della narrazione • Nov 10
MOVE: Revenue Will Hold Steady as Earnings Guidance Signals Further Upside
Narrative Update: Medacta Group Price Target Adjustment Analysts have slightly lowered their fair value estimate for Medacta Group from CHF164.46 to CHF164.40, citing minor model updates that reflect changes in discount rate assumptions. What's in the News Medacta Group SA confirmed its earnings guidance for 2025, targeting revenue growth of 16% to 18% in constant currency, subject to unforeseen events (Company Guidance).Articolo di analisi • Nov 08
Medacta Group (VTX:MOVE) Is Looking To Continue Growing Its Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Aggiornamento della narrazione • Oct 27
Earnings Guidance And Updated Outlook Will Drive Expansion Across New Markets
Analysts have raised their price target for Medacta Group from CHF156.91 to CHF164.46, citing modest adjustments to growth and margin expectations as reflected in updated forecasts. What's in the News Medacta Group SA confirmed its earnings guidance for 2025, targeting revenue growth in the range of 16% to 18% in constant currency, subject to unforeseen events (Key Developments).Articolo di analisi • Oct 21
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Oct 01
Investor Optimism Abounds Medacta Group SA (VTX:MOVE) But Growth Is Lacking
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...Articolo di analisi • Sep 13
Medacta Group's (VTX:MOVE) Solid Profits Have Weak Fundamentals
Medacta Group SA ( VTX:MOVE ) just reported some strong earnings, and the market reacted accordingly with a healthy...Articolo di analisi • Sep 12
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF150?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a decent share price growth...Articolo di analisi • Aug 29
Estimating The Fair Value Of Medacta Group SA (VTX:MOVE)
Key Insights Medacta Group's estimated fair value is CHF129 based on 2 Stage Free Cash Flow to Equity Current share...Articolo di analisi • Aug 01
Medacta Group (VTX:MOVE) Has Some Way To Go To Become A Multi-Bagger
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Articolo di analisi • Jun 24
Do Medacta Group's (VTX:MOVE) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Articolo di analisi • May 24
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it saw a significant share price rise of 23...Articolo di analisi • May 10
Market Participants Recognise Medacta Group SA's (VTX:MOVE) Earnings Pushing Shares 26% Higher
Medacta Group SA ( VTX:MOVE ) shareholders would be excited to see that the share price has had a great month, posting...Articolo di analisi • May 01
Medacta Group SA's (VTX:MOVE) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Medacta Group's Annual General Meeting to take place on 7th of May Total pay for CEO Francesco Siccardi...Articolo di analisi • Apr 24
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Apr 10
Return Trends At Medacta Group (VTX:MOVE) Aren't Appealing
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Articolo di analisi • Mar 28
Medacta Group SA (VTX:MOVE) Yearly Results: Here's What Analysts Are Forecasting For This Year
The full-year results for Medacta Group SA ( VTX:MOVE ) were released last week, making it a good time to revisit its...Articolo di analisi • Feb 13
Medacta Group SA (VTX:MOVE) Looks Just Right With A 25% Price Jump
Medacta Group SA ( VTX:MOVE ) shareholders would be excited to see that the share price has had a great month, posting...
Nuova narrazione • Feb 09
New Products Like GMK SpheriKA And NextAR Will Strengthen Future Prospects In The Spine Segment
Medacta's innovation in product launches and medical education expansion drives revenue growth, with a strong focus on the Spine segment and ASCs.Articolo di analisi • Jan 06
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Articolo di analisi • Nov 22
The Price Is Right For Medacta Group SA (VTX:MOVE)
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...Articolo di analisi • Oct 14
Is Medacta Group (VTX:MOVE) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Sep 06
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Key Insights Medacta Group's estimated fair value is CHF95.33 based on 2 Stage Free Cash Flow to Equity Current share...Articolo di analisi • Aug 21
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
While Medacta Group SA ( VTX:MOVE ) might not have the largest market cap around , it saw a double-digit share price...Articolo di analisi • Aug 06
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Articolo di analisi • Jun 20
Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
With a price-to-earnings (or "P/E") ratio of 54x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...Articolo di analisi • May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Key Insights Medacta Group will host its Annual General Meeting on 7th of May Total pay for CEO Francesco Siccardi...Articolo di analisi • Apr 17
Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Mar 29
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it received a lot of attention from a substantial...Articolo di analisi • Feb 22
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Articolo di analisi • Feb 07
Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Articolo di analisi • Dec 18
Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
With a price-to-earnings (or "P/E") ratio of 51.3x Medacta Group SA ( VTX:MOVE ) may be sending very bearish signals at...Articolo di analisi • Dec 04
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Key Insights The projected fair value for Medacta Group is CHF109 based on 2 Stage Free Cash Flow to Equity Medacta...Articolo di analisi • Nov 15
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...Articolo di analisi • Oct 30
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Articolo di analisi • Oct 17
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Sep 29
Is Medacta Group (VTX:MOVE) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Aug 11
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Key Insights The projected fair value for Medacta Group is CHF113 based on 2 Stage Free Cash Flow to Equity Medacta...Articolo di analisi • Jul 27
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...Articolo di analisi • Jul 03
Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Articolo di analisi • Apr 28
At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it led the SWX gainers with a relatively large...Articolo di analisi • Apr 08
Is Medacta Group (VTX:MOVE) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Dec 25
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Medacta Group SA ( VTX:MOVE ), is not the largest company out there, but it received a lot of attention from a...Articolo di analisi • Dec 09
Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Articolo di analisi • Nov 09
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Sep 16
Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
While Medacta Group SA ( VTX:MOVE ) might not be the most widely known stock at the moment, it received a lot of...Rendimenti per gli azionisti
| MOVE | CH Medical Equipment | CH Mercato | |
|---|---|---|---|
| 7D | -3.2% | -1.1% | 1.9% |
| 1Y | 0.7% | -19.0% | 10.4% |
Ritorno vs Industria: MOVE ha superato il Swiss Medical Equipment che ha restituito -19 % nell'ultimo anno.
Rendimento vs Mercato: MOVE ha avuto una performance inferiore al mercato Swiss che ha registrato un rendimento 10.4 % nell'ultimo anno.
Volatilità dei prezzi
| MOVE volatility | |
|---|---|
| MOVE Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.4% |
Prezzo delle azioni stabile: MOVE non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swiss.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di MOVE è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1958 | 2,036 | Francesco Siccardi | www.medacta.com |
Medacta Group SA sviluppa, produce e distribuisce dispositivi medici ortopedici e neurochirurgici in America Latina, Nord America, Asia-Pacifico, Medio Oriente e Africa. Offre strumenti di pianificazione 3D personalizzati per la chirurgia dell'anca, del ginocchio, della spalla, delle protesi articolari, della medicina sportiva e della colonna vertebrale. Medacta Group SA è stata fondata nel 1958 e ha sede a Castel San Pietro, in Svizzera.
Medacta Group SA Riepilogo dei fondamenti
| MOVE statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | CHF 2.68b |
| Utili (TTM) | CHF 88.00m |
| Ricavi(TTM) | CHF 630.38m |
30.4x
Rapporto P/E4.2x
Rapporto P/SMOVE è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MOVE Conto economico (TTM) | |
|---|---|
| Ricavi | €683.83m |
| Costo del fatturato | €225.17m |
| Profitto lordo | €458.66m |
| Altre spese | €363.20m |
| Utili | €95.46m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
Sep 09, 2026
| Utile per azione (EPS) | 4.79 |
| Margine lordo | 67.07% |
| Margine di profitto netto | 13.96% |
| Rapporto debito/patrimonio netto | 44.9% |
Come si è comportato MOVE nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.8%
Rendimento attuale del dividendo25%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/12 17:13 |
| Prezzo dell'azione a fine giornata | 2026/06/12 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Medacta Group SA è coperta da 12 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Samuel England | Berenberg |
| David Adlington | J.P. Morgan |
| Ilya Burgansky | Research Partners AG |